Copenhagen - Delayed Quote DKK

Genmab A/S (GMAB.CO)

3,912.00 +124.00 (+3.27%)

At close: October 30 at 4:59:38 PM GMT+1

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?

Simply Wall St. 2d ago

GMAB
Genmab’s bispecific halves risk of death in first-line HNSCC

Clinical Trials Arena 2d ago

GMAB
Genmab soars to record highs after cancer drug succeeds in key trial

BioPharma Dive 2d ago

GMAB
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

Insider Monkey 3mo ago

GMAB.CO
+3.27%
GMAB
$Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

GlobeNewswire 3mo ago

GMAB.CO
+3.27%
GMAB
$Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival$

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Business Wire 4mo ago

GMAB.CO
+3.27%
GMAB
$Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival$

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

GlobeNewswire 4mo ago

GMAB.CO
+3.27%
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise

GlobeNewswire 4mo ago

GMAB.CO
+3.27%
GMAB
Major Shareholder Announcement

GlobeNewswire 4mo ago

GMAB.CO
+3.27%
0MGB

GMAB
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside

Simply Wall St. 4mo ago

GMAB.CO
+3.27%
GMAB
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Business Wire 4mo ago

GMAB.CO
+3.27%
GMAB
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

GlobeNewswire 4mo ago

GMAB.CO
+3.27%
GMAB

0MGB

Performance Overview

Return	GMAB.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	+92.99%	+8.24%
1-Year	+110.44%	+15.77%
3-Year	+94.92%	+23.77%

U.S. markets closed

Genmab A/S (GMAB.CO)

Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?

Genmab’s bispecific halves risk of death in first-line HNSCC

Genmab soars to record highs after cancer drug succeeds in key trial

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Major Shareholder Announcement

Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)